ClinicalTrials.gg
CompletedNCT01658384CogMSUpdated Mar 6, 2019

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients

An observational study in Multiple Sclerosis, sponsored by Clinique Neuro-Outaouais. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-06.

Sponsored by Clinique Neuro-Outaouais · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
63
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 257 studies in Multiple Sclerosis with a site in Canada — 25 open to participants now, 43 under way, 12 of them phase 3. Multiple Sclerosis · Canada.

Enrollment
31st of 42
63 · median 172
Started
2011
with 10 others
Observational
42 of 257
2 open now
Registered
96th of 257
by date
Lead sponsor
6 of 257
Clinique Neuro-Outaouais

Among the 257 studies in Multiple Sclerosis with a site in Canada, this one is the 31st largest by enrollment of the 42 observational ones that give a count, is one of 11 that started in 2011, is one of 42 observational ones, and was the 96th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

25 of the 257 studies in Multiple Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 257 studies in Multiple Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

This study is designed to evaluate the effect of Tysabri on cognition in multiple sclerosis (MS) patients. During a period of 24 months, the study will assess the evolution of cognitive function in Tysabri treated MS patients using the Symbol Digit Modalities Test (SDMT) and the CogState battery of tests.

Read the detailed description

Tysabri reduces the relapse frequency, slows progression and preserves cognitive function as compared to placebo as per the AFFIRM trial. The benefit on relapse rate and progression appears to be sustained in longer-term studies such as STRATA. In clinical practice however despite a stable condition on the Expanded Disability Status Scale (EDSS) patients often complain of cognitive deterioration. It has yet to be shown that Tysabri will prevent cognitive deterioration after more than 2 years of treatment.

The Symbol Digit Modalities Test (SDMT) is a sensitive and validated test of cognition in MS. CogState offers a standardized battery of cognitive tests frequently used in clinical research in the fields of dementia and Parkinson's disease. The CogState battery of tests consisting of the Detection test (processing speed), Identification test (attention), One Back test (working memory), International Shopping List test (verbal learning) and the Groton Maze Learning test (reasoning and problem solving) will further confirm and validate the results of the Symbol Digit Modalities Test(SDMT) in MS patients as well as examine other cognitive parameters.

Together the above tests done prospectively can assess the evolution of cognitive function in Tysabri treated MS patients over the longer term.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with multiple sclerosis who are receiving Tysabri per indication.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with multiple sclerosis who are receiving Tysabri per indication and are willing and able to give an .

Exclusion criteria

Exclusion Criteria:

  • Patients who are depressed as per the Beck depression questionnaire at screening or at any time during the study.
  • Patients with cognitive decline from causes other than MS.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
63 participants (actual)

Groups and cohorts

  • cognitive evolution, observational,MS

    multiple sclerosis tysabri treated patients

06

What researchers measure

Primary outcomes

  1. SDMT CogState battery

    Monthly cognitive assessments

    Time frame: 2 years

07

Study locations

1 site
  • Clinique Neuro-Outaouais
    Gatineau, Quebec J9J 0A5, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Feb 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2011
First posted
Aug 7, 2012
Start
Sep 2011
Primary completionActual
Feb 2015
CompletionActual
Mar 2015
Last update
Mar 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01658384
Lead sponsor
Clinique Neuro-Outaouais
Collaborators
CogState Ltd.
Responsible party
Sponsor
First posted
Aug 7, 2012
Start date
Sep 2011
Primary completion
Feb 2015
Completion
Mar 2015
Last update
Mar 6, 2019

Study contacts

François H Jacques, MD
principal investigator · Clinique Neuro-Outaouais

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion